spironolactone has been researched along with Aortic Diseases in 6 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Aortic Diseases: Pathological processes involving any part of the AORTA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The beneficial effects of eplerenone, a specific mineralocorticoid receptor blocker, were previously demonstrated in early atherosclerosis (ATS)." | 7.78 | Eplerenone reduced lesion size in early but not advanced atherosclerosis in apolipoprotein E-deficient mice. ( Coleman, R; Gamliel-Lazarovich, A; Keidar, S; Raz-Pasteur, A, 2012) |
| "The beneficial effects of eplerenone, a specific mineralocorticoid receptor blocker, were previously demonstrated in early atherosclerosis (ATS)." | 3.78 | Eplerenone reduced lesion size in early but not advanced atherosclerosis in apolipoprotein E-deficient mice. ( Coleman, R; Gamliel-Lazarovich, A; Keidar, S; Raz-Pasteur, A, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Man, JJ | 1 |
| Lu, Q | 1 |
| Moss, ME | 1 |
| Carvajal, B | 1 |
| Baur, W | 1 |
| Garza, AE | 1 |
| Freeman, R | 1 |
| Anastasiou, M | 1 |
| Ngwenyama, N | 1 |
| Adler, GK | 1 |
| Alcaide, P | 1 |
| Jaffe, IZ | 1 |
| Rajagopalan, S | 1 |
| Alaiti, MA | 1 |
| Broadwater, K | 1 |
| Goud, A | 1 |
| Gaztanaga, J | 1 |
| Connelly, K | 1 |
| Fares, A | 1 |
| Shirazian, S | 1 |
| Kreatsoulas, C | 1 |
| Farkouh, M | 1 |
| Dobre, M | 1 |
| Fink, JC | 1 |
| Weir, MR | 1 |
| Tatsumoto, N | 1 |
| Yamada, S | 1 |
| Tokumoto, M | 1 |
| Eriguchi, M | 1 |
| Noguchi, H | 1 |
| Torisu, K | 1 |
| Tsuruya, K | 1 |
| Kitazono, T | 1 |
| Pitt, B | 1 |
| Raz-Pasteur, A | 1 |
| Gamliel-Lazarovich, A | 1 |
| Coleman, R | 2 |
| Keidar, S | 2 |
| Kaplan, M | 1 |
| Pavlotzky, E | 1 |
| Hayek, T | 1 |
| Hamoud, S | 1 |
| Aviram, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Spironolactone on the Progression of Coronary Calcification in Peritoneal Dialysis Patients[NCT03314493] | Phase 3 | 33 participants (Actual) | Interventional | 2014-11-07 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for spironolactone and Aortic Diseases
| Article | Year |
|---|---|
Design of the Magnetic Resonance Imaging Evaluation of Mineralocorticoid Receptor Antagonism in Diabetic Atherosclerosis (MAGMA) Trial.
Topics: Aorta, Thoracic; Aortic Diseases; Atherosclerosis; Clinical Protocols; Diabetes Mellitus, Type 2; Di | 2017 |
5 other studies available for spironolactone and Aortic Diseases
| Article | Year |
|---|---|
Myeloid Mineralocorticoid Receptor Transcriptionally Regulates P-Selectin Glycoprotein Ligand-1 and Promotes Monocyte Trafficking and Atherosclerosis.
Topics: Adult; Animals; Aorta, Thoracic; Aortic Diseases; Atherosclerosis; Cell Adhesion; Disease Models, An | 2021 |
Spironolactone ameliorates arterial medial calcification in uremic rats: the role of mineralocorticoid receptor signaling in vascular calcification.
Topics: Adenine; Animals; Aorta, Abdominal; Aortic Diseases; Apoptosis; Biomarkers; Disease Models, Animal; | 2015 |
Pharmacotherapy: Cardiovascular effects of aldosterone blockade in CKD.
Topics: Aortic Diseases; Chronic Disease; Humans; Hyperkalemia; Hypertrophy, Left Ventricular; Kidney Diseas | 2009 |
Eplerenone reduced lesion size in early but not advanced atherosclerosis in apolipoprotein E-deficient mice.
Topics: Animals; Aorta, Thoracic; Aortic Diseases; Apolipoproteins E; Atherosclerosis; Cytochrome P-450 CYP1 | 2012 |
Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2004 |